文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

北欧国家奥密克戎优势期异源第三剂疫苗方案对重症新冠的比较有效性:基于人群的队列分析

Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses.
PubMed 文献 · BMJ · 2023-07-24
一句话结论奥密克戎优势期,异源加强方案较仅基础免疫和同源mRNA加强均与更高的重症新冠保护相关。

该研究基于丹麦、芬兰、挪威和瑞典四国2020年12月27日至2022年12月31日的人群队列,纳入≥18岁、至少完成AZD1222或BNT162b2/mRNA-1273基础免疫的成年人,比较异源加强方案与仅基础方案及同源mRNA加强方案在奥密克戎优势期的疫苗有效性。随访为加强剂后第14天起75天,比较新冠相关住院、新冠死亡、ICU入住和SARS-CoV-2感染风险。异源加强较仅基础方案对新冠住院有效性为82.7%和81.5%,对新冠死亡为95.9%和87.5%;异源加强较同源加强对住院有效性为27.2%和23.3%,对死亡为21.7%和18.4%(置信区间跨0)。结论认为异源加强方案与更高的重症奥密克戎相关新冠结局保护相关。

要点

  • 奥密克戎优势期,异源加强(AZD1222+BNT162b2或mRNA-1273)较仅基础免疫对新冠住院有效性82.7%(95%CI 77.1%–88.2%),对新冠死亡95.9%(91.6%–100.0%)。
  • 异源加强(BNT162b2+mRNA-1273)较仅基础免疫对新冠住院有效性81.5%(78.9%–84.2%),对新冠死亡87.5%(82.5%–92.6%)。
  • 同源mRNA加强较仅基础免疫对新冠住院有效性≥76.5%,对新冠死亡≥84.1%。
  • 异源加强较同源加强对新冠住院有效性:AZD1222+BNT162b2或mRNA-1273为27.2%(3.7%–50.6%),BNT162b2+mRNA-1273为23.3%(15.8%–30.8%)。
  • 异源加强较同源加强对新冠死亡有效性:AZD1222+BNT162b2或mRNA-1273为21.7%(-8.3%–51.7%),BNT162b2+mRNA-1273为18.4%(-15.7%–52.5%),置信区间跨0。

适用人群与场景

  • 丹麦、芬兰、挪威和瑞典≥18岁成年人,已至少完成AZD1222或单价SARS-CoV-2野生型(祖先株)mRNA疫苗BNT162b2或mRNA-1273基础免疫(任意组合)。
  • 研究场景为奥密克戎优势期,2020年12月27日至2022年12月31日。

研究设计与关键结果

  • 研究类型:基于人群的队列分析,四国(丹麦、芬兰、挪威、瑞典)联合分析。
  • 暴露组:异源加强AZD1222+BNT162b2或mRNA-1273共1 086 418人;异源加强BNT162b2+mRNA-1273共2 505 093人。
  • 主要结局为新冠相关住院和新冠死亡的国家合并风险;次要结局为新冠相关ICU入住和SARS-CoV-2感染。
  • 随访为加强剂后第14天起75天;比较疫苗有效性=1-风险比。
  • 异源加强(AZD1222+BNT162b2或mRNA-1273)较仅基础免疫:新冠住院有效性82.7%(95%CI 77.1%–88.2%),新冠死亡有效性95.9%(91.6%–100.0%)。
  • 异源加强(BNT162b2+mRNA-1273)较仅基础免疫:新冠住院有效性81.5%(78.9%–84.2%),新冠死亡有效性87.5%(82.5%–92.6%)。
  • 同源mRNA加强较仅基础免疫:新冠住院有效性≥76.5%,新冠死亡有效性≥84.1%。
  • 异源加强较同源加强:AZD1222+BNT162b2或mRNA-1273对新冠住院有效性27.2%(3.7%–50.6%),对新冠死亡21.7%(-8.3%–51.7%);BNT162b2+mRNA-1273对新冠住院有效性23.3%(15.8%–30.8%),对新冠死亡18.4%(-15.7%–52.5%)。

证据类型、等级与局限

  • 证据类型:基于人群的队列分析(匹配分析和加权分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论认为,与基础免疫方案和同源加强方案相比,异源加强方案与更高的重症奥密克戎相关新冠结局保护相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the comparative vaccine effectiveness of heterologous booster schedules (ie, three vaccine doses) compared with primary schedules (two vaccine doses) and with homologous mRNA vaccine booster schedules (three vaccine doses) during a period of omicron predominance.

DESIGN: Population based cohort analyses.

SETTING: Denmark, Finland, Norway, and Sweden, 27 December 2020 to 31 December 2022.

PARTICIPANTS: All adults aged ≥18 years who had received at least a primary vaccination schedule of AZD1222 (Oxford-AstraZeneca) or monovalent SARS-CoV-2 wild type (ancestral) strain based mRNA vaccines BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna), in any combination.

MAIN OUTCOME MEASURES: The main outcome measure was country combined risks of covid-19 related hospital admission and death with covid-19 and additional outcomes of covid-19 related admission to an intensive care unit and SARS-CoV-2 infection. During a period of omicron predominance, these outcomes were compared in those who received a heterologous booster versus primary schedule (matched analyses) and versus those who received a homologous mRNA vaccine booster (weighted analyses). Follow-up was for 75 days from day 14 after the booster dose; comparative vaccine effectiveness was calculated as 1-risk ratio.

RESULTS: Across the four Nordic countries, 1 086 418 participants had received a heterologous booster schedule of AZD1222+BNT162b2 or mRNA-1273 and 2 505 093 had received a heterologous booster schedule of BNT162b2+mRNA-1273. Compared with the primary schedule only (two doses), the vaccine effectiveness of heterologous booster schedules comprising AZD1222+BNT162b2 or mRNA-1273 and BNT162b2+mRNA-1273 was 82.7% (95% confidence interval 77.1% to 88.2%) and 81.5% (78.9% to 84.2%) for covid-19 related hospital admission and 95.9% (91.6% to 100.0%) and 87.5% (82.5% to 92.6%) for death with covid-19, respectively. Homologous mRNA booster schedules were similarly associated with increased protection against covid-19 related hospital admission (≥76.5%) and death with covid-19 (≥84.1%) compared with previous primary course vaccination only. When a heterologous booster schedule was compared with the homologous booster schedule, vaccine effectiveness was 27.2% (3.7% to 50.6%) for AZD1222+BNT162b2 or mRNA-1273 and 23.3% (15.8% to 30.8%) for BNT162b2+mRNA-1273 schedules against covid-19 related hospital admission and 21.7% (-8.3% to 51.7%) and 18.4% (-15.7% to 52.5%) against death with covid-19, respectively.

CONCLUSION: Heterologous booster schedules are associated with increased protection against severe, omicron related covid-19 outcomes compared with primary course schedules and homologous booster schedules.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Andersson NW, Thiesson EM, Baum U, et al. Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses. BMJ. 2023. PMID: 37487623. doi:10.1136/bmj-2022-074325

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。